Boston Scientific director buys 5,000 shares

Boston Scientific Corp director Edward J. Ludwig purchased 5,000 shares of common stock on July 31, 2026 at an average price of $45.4799 per share.

Accepted by SEC EDGAR 08/03/2026 - 04:29 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Boston Scientific Corp director Edward J. Ludwig purchased 5,000 shares of common stock on July 31, 2026 at an average price of $45.4799 per share. After this open-market or private transaction, he directly owns 30,359 shares. The trade was not reported under a Rule 10b5-1 plan.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider LUDWIG EDWARD J

Role Director

Bought 5,000 shs ($227K)

Increase in Position 19.7%

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$45.4799	$227K

Holdings After Transaction: Common Stock — 30,359 shares (Direct)

Holdings Before and After: Common Stock, 25,359 to 30,359 shares (Direct)

Key Figures

Shares purchased: 5,000 shares Purchase price: $45.4799 per share Shares owned after transaction: 30,359 shares +1 more

4 metrics

Shares purchased 5,000 shares Common Stock transaction on July 31, 2026

Purchase price $45.4799 per share Average price for the 5,000-share purchase

Shares owned after transaction 30,359 shares Directly held Boston Scientific common stock after the purchase

Net insider buying 5,000 shares Net buy shares reported in transactionSummary (net-buy direction)

Key Terms

Rule 10b5-1, open market or private transaction, direct or indirect ownership

3 terms

Rule 10b5-1 regulatory

"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction market

"transaction_code_description: Purchase in open market or private transaction"

direct or indirect ownership financial

"direct_or_indirect uses D/I for Direct/Indirect ownership type"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edward J. Ludwig report for BSX?

Edward J. Ludwig reported a purchase of 5,000 shares of Boston Scientific common stock on July 31, 2026. This was recorded as an open-market or private transaction and increased his directly held stake in the company.

How many BSX shares did Edward J. Ludwig buy and at what price?

Edward J. Ludwig bought 5,000 Boston Scientific (BSX) shares at an average price of $45.4799 per share. The transaction is classified as a purchase in an open-market or private transaction, according to the filing data.

What are Edward J. Ludwig’s total BSX holdings after this trade?

Following the reported transaction, Edward J. Ludwig directly owns 30,359 shares of Boston Scientific common stock. This total reflects his position immediately after purchasing 5,000 shares on July 31, 2026, as disclosed in the Form 4 data.

Was Edward J. Ludwig’s BSX share purchase under a Rule 10b5-1 plan?

The transaction was not reported under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is marked false, indicating the reported purchase was not executed pursuant to an affirmed trading plan.

Is Edward J. Ludwig’s BSX ownership direct or indirect after the trade?

The filing classifies his post-transaction holdings as direct ownership. The 30,359 Boston Scientific shares reported following the purchase are coded with ownership type "D" for Direct, with no nature-of-ownership footnote qualifiers attached.

What is the net effect of the reported insider trading activity in BSX?

The net effect is a net buy of 5,000 shares by Edward J. Ludwig. Transaction summary data shows one purchase transaction, no sales, and net-buy direction, increasing his direct holdings of Boston Scientific common stock to 30,359 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LUDWIG EDWARD J

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		P		5,000	A	$45.4799	30,359	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Susan Thompson, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)